IL6 and COVID-19: Finally, In the international, multifactorial, adaptive platform trial REMAP-CAP (NCT02735707), both tocilizumab and sarilumab (another IL-6 inhibitor), met predefined criteria for efficacy against COVID-19 in critically ill patients receiving organ support in ICU.